Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
However, the TRIUMPH-1 Phase 3 trial results indicated significant weight loss, with participants losing up to 28.3% of their body weight at 80 weeks
Circulation 142:12051218
CagriSema combination profile When cagrilintide is combined with semaglutide, the weight loss results are substantially better, averaging 20.4% body weight reduction versus 11.8% with cagrilintide alone
Weight-loss outcomes supported by peer-reviewed clinical data Naturally helps curb appetite and minimize unnecessary snacking Encourages a more efficient metabolism and consistent daily energy Supports healthier insulin function and more stable blood-sugar patterns Promotes lasting fullness to help reduce overeating GLP-1s work with your body's natural biology to support meaningful, sustainable weight loss
With subcutaneous injection, these central and peripheral effects occur simultaneously because the peptide distributes throughout the body via systemic circulation
Many people describe this phase as a gentle introduction rather than a dramatic change
